Mitomycin 40 mg/80mL (Mitomycin INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION) 40 mg/80mL

Mitomycin 40 mg/80mL is a lyophilized powder for solution, used for intravenous administration. This medication is commonly associated with certain cancer treatments and is supplied in a unit-dose vial.

Strength

40 mg/80mL

Pack Size

1 VIAL in 1 BOX, UNIT-DOSE (0143-9280-01) / 80 mL in 1 VIAL

Manufacturer / TM Owner

Hikma Pharmaceuticals USA Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Mitomycin is primarily used in the management of specific types of cancer. It works by interfering with the growth of cancer cells. The exact uses of Mitomycin 40 mg/80mL should be determined by a healthcare provider based on individual patient needs.

Side Effects

Common effects of Mitomycin may include nausea, vomiting, and fatigue. Some individuals may also experience hair loss or changes in blood cell counts. Always consult a healthcare provider for personalized information.

Precautions & Warnings

Mitomycin should be handled with care, as it is a potent medication. It is important to follow proper safety protocols when preparing and administering this injection. Patients should discuss their medical history with a healthcare provider before use.

Avoid Interactions

Mitomycin may interact with other medications, including certain chemotherapy drugs. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Always follow the advice of a healthcare professional.

Frequently Asked Questions

Mitomycin is commonly used in the treatment of certain types of cancer. It works by interfering with the growth of cancer cells.

Mitomycin 40 mg/80mL is administered intravenously after reconstitution. It is important to follow the instructions provided by a healthcare provider.

Common side effects may include nausea, vomiting, fatigue, and hair loss. Always consult a healthcare provider for personalized information.

Mitomycin may interact with other medications, including certain chemotherapy drugs. It is important to inform your healthcare provider about all medications you are taking.

Mitomycin should be handled with care, as it is a potent medication. It is important to follow proper safety protocols when preparing and administering this injection.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.